Baby on board? evaluating perinatal hepatitis b surveillance, New Jersey 2010-2011
Methods: The surveillance system was evaluated with a focus on sensitivity of at-risk infant identification. Clinical management completion was also analyzed. To evaluate electronic birth certificates (EBC), a representative reporting source, and its review process, EBC data were matched to surveillance data. To evaluate as a potential reporting source, independent hospital discharge data were matched to surveillance data.
Results: Of 805 infants with confirmed perinatal HBV exposure, 787 (98%) received the birth dose of the HBV vaccine and 754 (94%) received HBIG within one calendar day of birth. Among 714 infants residing in NJ during clinical management, 504 (71%) completed HBV vaccine series by age 8 months. Evaluation of EBC data identified 513 at-risk infants; of these 421 were reported in the surveillance system and 92 were not. Evaluation of hospital discharge data identified 484 at-risk infants; of these 192 were not identified in the surveillance system.
Conclusions: Hospital discharge data can be a useful additional reporting source to improve surveillance of at-risk infants.
Learning Areas:Chronic disease management and prevention
Conduct evaluation related to programs, research, and other areas of practice
Public health or related research
Describe perinatal hepatitis B surveillance system in NJ during 2010 to 2011 Describe characteristics of at-risk infants reported to program Evaluate one current and one potential reporting source for surveillance system
Keyword(s): Surveillance, Hepatitis B
Qualified on the content I am responsible for because: I have been the lead in several projects related to the perinatal hepatitis B prevention program and other projects in the Communicable Disease Service at the New Jersey Department of Health. My work has focused on perinatal hepatitis B epidemiology, surveillance and hospital policies.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.